Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precision Biosciences Inc

4.80
-0.0900-1.84%
Post-market: 4.800.00000.00%18:54 EDT
Volume:120.21K
Turnover:590.69K
Market Cap:53.22M
PE:-1.72
High:5.12
Open:4.99
Low:4.72
Close:4.89
Loading ...

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Business Wire
·
01 May

Precision BioSciences (DTIL) Receives a Buy from H.C. Wainwright

TIPRANKS
·
01 May

BRIEF-Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
29 Apr

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

Zacks
·
16 Apr

Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV

MT Newswires Live
·
15 Apr

Precision BioSciences receives FDA fast track designation for PBGENE-HBV

TIPRANKS
·
15 Apr

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Business Wire
·
15 Apr

TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Zacks
·
10 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
26 Mar

Precision BioSciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Mar

BRIEF-Precision Biosciences Reports Fourth Quarter And FY 2024 Results

Reuters
·
26 Mar

Precision BioSciences: Q4 Earnings Snapshot

Associated Press Finance
·
26 Mar

As Of December 31, 2024, Precision BioSciences Had Approximately $108.5M In Cash, Cash Equivalents, And Restricted Cash, With Expected Cash Runway Into The Second Half Of 2026

Benzinga
·
26 Mar

Precision BioSciences Q4 2024 GAAP EPS $(2.22) Misses $(1.96) Estimate, Sales $638.00K May Not Be Comparable To $4.28M Estimate

Benzinga
·
26 Mar

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Business Wire
·
26 Mar

Precision BioSciences Inc expected to post a loss of $1.96 a share - Earnings Preview

Reuters
·
24 Mar

Precision BioSciences Inc expected to post a loss of $1.96 a share - Earnings Preview

Reuters
·
21 Mar

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Business Wire
·
21 Mar